RCD news
Integra Therapeutics, an advanced therapy biotech company, closes an EUR 10.7 million funding round for the development of its gene writing platform
Integra Therapeutics, an advanced therapy biotech company, has closed an EUR 10.7 million funding round with the aim of incorporating new advances in the development of its FiCAT gene writing platform
In addition, the new funds will allow for the preclinical validation of several next-generation CAR-T therapies and expand FiCAT's production capacity to facilitate its technology transfer to the pharmaceutical industry. At the same time, Integra is developing its first gene therapy for a rare paediatric liver disease.
A team led by David Pintos advised Integra Therapeutics on this transaction.
